Clinical proteomics and breast cancer

Surgeon

Volumn 13, Issue 5, 2015, Pages 271-278

  Zeidan, Bashar A ^a   Townsend, Paul A ^b   Garbis, Spiros D ^a   Copson, Ellen ^a   Cutress, Ramsey I ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Biomarkers; Breast cancer; Mass spectrometry; Proteomics; Review

Indexed keywords

TUMOR MARKER;

BREAST NEOPLASMS; FEMALE; HUMAN; MEDICAL RESEARCH; METABOLISM; PROCEDURES; PROGNOSIS; PROTEOMICS;

BIOMARKERS, TUMOR; BIOMEDICAL RESEARCH; BREAST NEOPLASMS; FEMALE; HUMANS; PROGNOSIS; PROTEOMICS;

EID: 84941175919     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surge.2014.12.003     Document Type: Review

References (31)

1. Cancer Research UK. Cancer statistics report: cancer incidence and mortality in the UK., vol. 2013, 2013.
2. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
4. Boyle P., Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol Off J Eur Soc Med Oncol/ESMO 2005, 16:481-488.
5. Varga D., Koenig J., Kuhr K., Strunz K., Geyer V., Kurzeder C., et al. Comparison of early onset breast cancer patients to older premenopausal breast cancer patients. Arch Gynecol Obstet 2010, 282:427-432.
6. Lawrence G., Wallis M., Allgood P., Nagtegaal I.D., Warwick J., Cafferty F.H., et al. Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias. Breast Cancer Res Treat 2009, 116:179-185.
7. Ludwig J.A., Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005, 5:845-856.
8. Sawyers C.L. The cancer biomarker problem. Nature 2008, 452:548-552.
9. Zeidan B.A., Townsend P.A. SELDI-TOF proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Res BCR 2008, 10:107.
10. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
11. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat Med 2004, 10:789-799.
12. McCoy R.G., Nair K.S. The 2010 ESPEN Sir David Cuthbertson Lecture: new and old proteins: clinical implications. Clin Nutr 2013, 32:728-736.
13. Zeidan B.A., Cutress R.I., Murray N., Coulton G.R., Hastie C., Packham G., et al. Proteomic analysis of archival breast cancer serum. Cancer Genomics Proteomics 2009, 6:141-147.
14. Laronga C., Becker S., Watson P., Gregory B., Cazares L., Lynch H., et al. SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis Markers 2003, 19:229-238.
15. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002, 48:1296-1304.
16. Li J., Orlandi R., White C.N., Rosenzweig J., Zhao J., Seregni E., et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 2005, 51:2229-2235.
17. Villanueva J., Shaffer D.R., Philip J., Chaparro C.A., Erdjument-Bromage H., Olshen A.B., et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006, 116:271-284.
18. Pusztai L., Gregory B.W., Baggerly K.A., Peng B., Koomen J., Kuerer H.M., et al. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 2004, 100:1814-1822.
19. Pawlik T.M., Fritsche H., Coombes K.R., Xiao L., Krishnamurthy S., Hunt K.K., et al. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat 2005, 89:149-157.
20. Becker S., Cazares L.H., Watson P., Lynch H., Semmes O.J., Drake R.R., et al. Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol 2004, 11:907-914.
21. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
22. Brozkova K., Budinska E., Bouchal P., Hernychova L., Knoflickova D., Valik D., et al. Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Res BCR 2008, 10:R48.
23. Katchman B.A., Ocal I.T., Cunliffe H.E., Chang Y.H., Hostetter G., Watanabe A., et al. Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in Luminal B breast cancer. Breast Cancer Res BCR 2013, 15:R28.
24. Cawthorn T.R., Moreno J.C., Dharsee M., Tran-Thanh D., Ackloo S., Zhu P.H., et al. Proteomic analyses reveal high expression of decorin and endoplasmin (HSP90B1) are associated with breast cancer metastasis and decreased survival. PLoS One 2012, 7:e30992.
25. Duffy M.J., O'Grady P., Devaney D., O'Siorain L., Fennelly J.J., Lijnen H.R. Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 1988, 48:1348-1349.
26. Descotes F., Jezequel P., Spyratos F., Campion L., Grenot C., Lerebours F., et al. Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: a multicentric 2004 national PHRC study. Int J Oncol 2012, 41:92-104.
27. He W., Tong Y., Wang Y., Liu J., Luo G., Wu J., et al. Serum soluble CD14 is a potential prognostic indicator of recurrence of human breast invasive ductal carcinoma with Her2-enriched subtype. PLoS One 2013, 8:e75366.
28. Johansson H.J., Sanchez B.C., Mundt F., Forshed J., Kovacs A., Panizza E., et al. Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun 2013, 4:2175.
29. Apweiler R., Aslanidis C., Deufel T., Gerstner A., Hansen J., Hochstrasser D., et al. Approaching clinical proteomics: current state and future fields of application in cellular proteomics. Cytom Part A J Int Soc Anal Cytol 2009, 75:816-832.
30. Fuzery A.K., Levin J., Chan M.M., Chan D.W. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics 2013, 10:13.
31. Harbeck N., Schmitt M., Meisner C., Friedel C., Untch M., Schmidt M., et al. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 2013, 49:1825-1835.